Skip Navigation



The European Journal of Public Health Advance Access published online on February 9, 2006
The European Journal of Public Health, doi:10.1093/eurpub/cki163
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
16/2/185    most recent
cki163v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Siebert, U.
Right arrow Articles by Goldie, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siebert, U.
Right arrow Articles by Goldie, S. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.
Received December 9, 2004
Accepted June 7, 2005

Article

The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany

Uwe Siebert 1 *, Gaby Sroczynski 1, Peter Hillemanns 2, Jutta Engel 3, Roland Stabenow 4, Christa Stegmaier 5, Kerstin Voigt 6, Bernhard Gibis 5, Dieter Hölzel 7, and Sue J. Goldie 6

1 Department of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University of Health Sciences, Medical Informatics and Technology, Hall i.T., Austria; Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA; Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Program on Health Technology Assessment and Decision Sciences, Institute of Medical Informatics, Biostatistics, and Epidemiology, Ludwig-Maximilians-University Munich, Germany
2 Department of Obstetrics and Gynecology, Friedrich-Schiller University of Jena, Jena, Germany
3 Munich Cancer Registry of the Munich Comprehensive Cancer Centre, Ludwig-Maximilians-University and Technical University of Munich, Munich, Germany
4 Common Cancer Registry of the Federal States Berlin/Brandenburg/Mecklenburg-Vorpommern/Sachsen-Anhalt/Sachsen/Thüringen, Berlin, Germany
5 Saarland Cancer Registry, Saarbrücken, Germany
6 Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
7 National Department for Health Care Quality, National Association of Statutory Health Insurance Physicians, Berlin, Germany

* To whom correspondence should be addressed.
Uwe Siebert, E-mail: uwe.siebert{at}umit.at


  Abstract

Background: We sought to develop and validate a decision-analytic model for the natural history of cervical cancer for the German health care context and to apply it to cervical cancer screening. Methods: We developed a Markov model for the natural history of cervical cancer and cervical cancer screening in the German health care context. The model reflects current German practice standards for screening, diagnostic follow-up and treatment regarding cervical cancer and its precursors. Data for disease progression and cervical cancer survival were obtained from the literature and German cancer registries. Accuracy of Papanicolaou (Pap) testing was based on meta-analyses. We performed internal and external model validation using observed epidemiological data for unscreened women from different German cancer registries. The model predicts life expectancy, incidence of detected cervical cancer cases, lifetime cervical cancer risks and mortality. Results: The model predicted a lifetime cervical cancer risk of 3.0% and a lifetime cervical cancer mortality of 1.0%, with a peak cancer incidence of 84/100 000 at age 51 years. These results were similar to observed data from German cancer registries, German literature data and results from other international models. Based on our model, annual Pap screening could prevent 98.7% of diagnosed cancer cases and 99.6% of deaths due to cervical cancer in women completely adherent to screening and compliant to treatment. Extending the screening interval from 1 year to 2, 3 or 5 years resulted in reduced screening effectiveness. Conclusions: This model provides a tool for evaluating the long-term effectiveness of different cervical cancer screening tests and strategies.

Keywords: cervical cancer; decision analysis; Markov model; screening.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Public HealthHome page
G. Sroczynski, E. Esteban, A. Conrads-Frank, R. Schwarzer, N. Muhlberger, D. Wright, S. Zeuzem, and U. Siebert
Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection
Eur J Public Health, June 1, 2009; 19(3): 245 - 253.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.